Evidence map›Paper›PMID 42792056›Full record

ArticleAntibiotics (Basel, Switzerland)2026

Clinical, Microbiological and Genomic Characterization of OXA-48-Producing

Simone Giuliano, Chiara Moreal, Michela Bulfoni, Jacopo Angelini, Valeria Fox, Nicolò Gualandi, Cinzia Lombardo, Francesco Curcio, Corrado Pipan, Carlo Federico Perno and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simone GiulianoInfectious Disease Clinic, University Hospital Friuli Centrale, 33100 Udine, Italy.ORCID 0000-0003-2475-8732
Chiara MorealDepartment of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0001-7926-7581
Michela BulfoniDepartment of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0003-2646-4228
Jacopo AngeliniDepartment of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0002-8433-0394
Valeria FoxMultimodal Laboratory Medicine, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.ORCID 0000-0002-4552-8461
Nicolò GualandiDepartment of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0003-0622-6118
Cinzia LombardoInfectious Disease Clinic, University Hospital Friuli Centrale, 33100 Udine, Italy.
Francesco CurcioDepartment of Medicine, University of Udine, 33100 Udine, Italy.ORCID 0000-0002-9070-4807
Corrado PipanDepartment of Medicine, University of Udine, 33100 Udine, Italy.
Carlo Federico PernoMicrobiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Francesco SerinoUOS Malattie Infettive, U.O.C. Medicina Generale, Portogruaro Hospital, 30026 Venice, Italy.
Paolo CesselliDepartment of Laboratory Medicine, Azienda Ulss 4 Veneto Orientale, 30026 Portogruaro, Italy.
Carlo TasciniInfectious Disease Clinic, University Hospital Friuli Centrale, 33100 Udine, Italy.ORCID 0000-0001-9625-6024
Paolo GaibaniMicrobiology and Virology Unit, Department of Pathology, Azienda Ospedaliera Universitaria Integrata di Verona, 37134 Verona, Italy.ORCID 0000-0003-3791-8635

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThis study aimed to characterize the epidemiology, resistance, virulence determinants, and genomic relatedness of OXA-48-producing

methodsWe performed a retrospective observational study of consecutive, non-duplicate isolates (September 2024-January 2025). Susceptibility testing was performed using VITEK

resultsThirteen isolates were recovered from elderly, highly comorbid inpatients, mainly from urine (46.2%) and rectal/fecal screening (38.5%). Twelve patients were classified as colonized, whereas one patient had an infection due to OXA-48-producing

conclusionsWe identified a multidrug-resistant OXA-48-producing

Indexed as

carbapenemase-producing Enterobacteralescefepime/zidebactamgenomic surveillanceIncL plasmidintestinal colonizationsequence type 395

Identifiers

PMID42792056
PMCPMC13603657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.